期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
外泌体相关作用因子在结直肠癌诊治中的研究进展 被引量:3
1
作者 王白燕 卫耀斌 +3 位作者 杨艺 王磊 董然然(综述) 冯书营(审校) 《中国肿瘤临床》 CAS CSCD 北大核心 2023年第12期643-648,共6页
结直肠癌是最常见的消化系统恶性肿瘤之一,且近年来呈现上升和年轻态趋势。针对结直肠癌的治疗,除传统的手术、放疗、化疗等手段外,免疫治疗和靶向治疗已成为当前临床的研究热点,其中肿瘤源性外泌体在结直肠癌诊治过程中的优势逐渐凸显... 结直肠癌是最常见的消化系统恶性肿瘤之一,且近年来呈现上升和年轻态趋势。针对结直肠癌的治疗,除传统的手术、放疗、化疗等手段外,免疫治疗和靶向治疗已成为当前临床的研究热点,其中肿瘤源性外泌体在结直肠癌诊治过程中的优势逐渐凸显,参与了肿瘤的发生发展、侵袭和转移过程,可作为结直肠癌的诊断标志物、细胞间信息媒介和药物载体,在结直肠癌的免疫治疗和靶向治疗中发挥重要作用。但外泌体(exosome,Exo)在临床应用中还面临着诸多挑战和问题。本文将对Exo在结直肠癌诊治过程中相关因子的作用,包括作为生物标志物、载体功能、介导耐药、免疫调节、促血管生成等功能进行系统性综述,使其更好应用于结直肠癌的早期诊断、治疗和预后监测等,也为其他肿瘤的诊治提供借鉴。 展开更多
关键词 结直肠癌 外泌体 相关因子 标志物 纳米载体
下载PDF
Management of cytokine release syndrome related to CAR-T cell therapy 被引量:21
2
作者 Hongli Chen Fangxia wang +16 位作者 Pengyu Zhang Yilin Zhang Yinxia Chen Xiaohu Fan Xingmei Cao Jie Liu Yun Yang baiyan wang Bo Lei Liufang Gu Ju Bai Lili Wei Ruili Zhang Qiuchuan Zhuang wanggang Zhang Wanhong Zhao Aili He 《Frontiers of Medicine》 SCIE CAS CSCD 2019年第5期610-617,共8页
Chimeric antigen receptor T (CAR-T) cell therapy is a novel cellular immunotherapy that is widely used to treat hematological malignancies, including acute leukemia, lymphoma, and multiple myeloma. Despite its remarka... Chimeric antigen receptor T (CAR-T) cell therapy is a novel cellular immunotherapy that is widely used to treat hematological malignancies, including acute leukemia, lymphoma, and multiple myeloma. Despite its remarkable clinical effects, this therapy has side effects that cannot be underestimated. Cytokine release syndrome (CRS) is one of the most clinically important and potentially life-threatening toxicities. This syndrome is a systemic immune storm that involves the mass cytokines releasing by activated immune cells. This phenomenon causes multisystem damages and sometimes even death. In this study, we reported the management of a patient with recurrent and refractory multiple myeloma and three patients with acute lymphocytic leukemia who suffered CRS during CAR-T treatment. The early application of tocilizumab, an anti-IL-6 receptor antibody, according to toxicity grading and clinical manifestation is recommended especially for patients who suffer continuous hyperpyrexia, hypotensive shock, acute respiratory failure, and whose CRS toxicities deteriorated rapidly. Moreover, low doses of dexamethasone (5-10 mg/day) were used for refractory CRS not responding to tocilizumab. The effective management of the toxicities associated with CRS will bring additional survival opportunities and improve the quality of life for patients with cancer. 展开更多
关键词 CHIMERIC ANTIGEN RECEPTOR T cell CYTOKINE release SYNDROME TOCILIZUMAB
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部